Close Menu
NEW YORK (GenomeWeb News) - Vermillion said yesterday that it has regained compliance for listing on the Nasdaq Stock Market by retaining a market value of $35 million for a period of ten consecutive business days.
 
In August, Nasdaq notified the company, which was called Ciphergen at the time, that it was out of compliance with Nasdaq Marketplace Rule 4310(c)(3) due to insufficient market value.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.